Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial
Authors
Hanna, CKurian, KM
Williams, K
Watts, C
Jackson, A
Carruthers, R
Strathdee, K
Cruickshank, G
Dunn, L
Erridge, S
Godfrey, L
Jefferies, S
McBain, Catherine A
Sleigh, R
McCormick, A
Pittman, M
Halford, S
Chalmers, AJ
Affiliation
Institute of Cancer Sciences, University of Glasgow, United Kingdom.Issue Date
2020
Metadata
Show full item recordCitation
Hanna C, Kurian KM, Williams K, Watts C, Jackson A, Carruthers R, et al. Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro Oncol. 2020.Journal
Neuro-OncologyDOI
10.1093/neuonc/noaa104PubMed ID
32347934Additional Links
https://dx.doi.org/ 10.1093/neuonc/noaa104Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/neuonc/noaa104